Roivant Sciences (ROIV) Depreciation & Amortization (CF) (2021 - 2026)
Roivant Sciences' (ROIV) quarterly Depreciation & Amortization (CF) came in at $600000.0 in Q2 2026, down 45.36% on a YoY basis from $1.1 million in Q2 2025, and down 77.86% quarter-over-quarter from $2.7 million in Q4 2025.
Analysis
Roivant Sciences (ROIV) Depreciation & Amortization (CF) (2021 - 2026) Analysis & Trends
Roivant Sciences (ROIV) has reported Depreciation & Amortization (CF) for 6 consecutive years, with $600000.0 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Depreciation & Amortization (CF) fell 45.36% year-over-year to $600000.0; the trailing twelve-month figure through Jun 2026 stood at $4.2 million (down 77.24% YoY), and the FY2026 full-year result was $3.3 million, down 76.21% from the prior year.
- Depreciation & Amortization (CF) slipped to $600000.0 in Q2 2026 per ROIV's latest filing, from $2.7 million in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $16.8 million in Q4 2023 and bottomed at $600000.0 in Q2 2026.
- Historically, Depreciation & Amortization (CF) has averaged $5.9 million across 5 years, with a median of $4.9 million in 2024.
- The sharpest annual moves came in 2022 and 2025: Depreciation & Amortization (CF) jumped 205.35% in 2022, then tumbled 80.98% in 2025.
- Over 5 years, Depreciation & Amortization (CF) stood at $12.9 million in 2022, then soared by 30.28% to $16.8 million in 2023, then decreased by 24.78% to $12.6 million in 2024, then sank by 78.57% to $2.7 million in 2025, then sank by 77.86% to $600000.0 in 2026.
- According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $600000.0, $2.7 million, and $921000.0 for Q2 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 212.13 Bn | 198.14 Bn | 7.24 Bn | 1.11 Bn |
| 2 | Gilead Sciences | 181.29 Bn | 178.11 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 132.34 Bn | 124.49 Bn | 2.84 Bn | 56.50 Mn |
| 4 | Regeneron Pharmaceuticals | 82.70 Bn | 74.71 Bn | 3.93 Bn | 123.70 Mn |
| 5 | Argenx Se | 61.60 Bn | 56.42 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.61 Bn | 49.48 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 33.96 Bn | 30.65 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.26 Bn | 29.97 Bn | 1.96 Bn | 236.10 Mn |
| 9 | Roivant Sciences | 29.96 Bn | 29.96 Bn | 1.16 Mn | 600,000.00 |
| 10 | Insmed | 28.16 Bn | 27.00 Bn | 358.27 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 600,000.00 |
| Dec 31, 2025 | 2.71 Mn |
| Sep 30, 2025 | 921,000.00 |
| Jun 30, 2025 | 1.10 Mn |
| Dec 31, 2024 | 12.65 Mn |
| Sep 30, 2024 | 4.84 Mn |
| Jun 30, 2024 | 4.88 Mn |
| Dec 31, 2023 | 16.81 Mn |
| Sep 30, 2023 | 5.59 Mn |
| Jun 30, 2023 | 5.84 Mn |
| Dec 31, 2022 | 12.90 Mn |
| Sep 30, 2022 | 5.08 Mn |
| Jun 30, 2022 | 2.68 Mn |
| Dec 31, 2021 | 4.23 Mn |